BCIQ Profiles

Company Profile Report
0301 Debiopharm Merck KGaA
BioCentury & Getty Images


With Phase III started in head and neck cancer, Debiopharm partners lead program with Germany’s Merck

Mar 1, 2021 | 10:00 PM GMT

Debiopharm will bank €188 million ($226.6 million) for pipeline development now that the biotech has partnered lead program xevinapant with Merck KGaA, adding the

Read the full 536 word article

How to gain access

Continue reading with a
two-week free trial.